Minimally invasive interventional treatment of tumor under imaging guidance can inactivate the lesion in situ with less trauma and protect the physiological function of the patient to the greatest extent, and its therapeutic effect is comparable to that of open surgery. In some cases, malignant tumor is regarded as a systemic disease, and even after complete resection or minimally invasive in situ inactivation of tumor, there is still a possibility of metastasis to other parts of the body, therefore, it is necessary to identify the genetic mutation site of tumor and adopt “targeted drug therapy” to inhibit the growth of tumor. Biological immunotherapy” can also be combined with “biological immunotherapy” to improve the overall immune function of patients to control the recurrence and metastasis of tumor. The combination of local minimally invasive interventional therapy with targeted drug and bioimmunotherapy can change the previous destructive treatment mode to active constructive treatment mode, which can benefit patients more and truly realize the comprehensive individualized treatment of minimally invasive interventional tumor.